Abstract
Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA. Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA. Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples. Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and Sézary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83%. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46). Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1389-1397 |
| Number of pages | 9 |
| Journal | Journal of Veterinary Internal Medicine |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2006 |
| Externally published | Yes |
Fingerprint
Keywords
- Alkylator
- Chemotherapy
- Epitheliotropic lymphoma
- Mycosis fungoides
- Nitrosourea
- Skin
ASJC Scopus subject areas
- veterinary(all)
Cite this
Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU) : A retrospective study of 46 cases (1999-2004). / Risbon, Rebecca E.; De Lorimier, L. P.; Skorupski, Katherine A; Burgess, K. E.; Bergman, P. J.; Carreras, J.; Hahn, K.; LeBlanc, A.; Turek, M.; Impellizeri, J.; Fred, R.; Wojcieszyn, J. W.; Drobatz, K.; Clifford, C. A.
In: Journal of Veterinary Internal Medicine, Vol. 20, No. 6, 11.2006, p. 1389-1397.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU)
T2 - A retrospective study of 46 cases (1999-2004)
AU - Risbon, Rebecca E.
AU - De Lorimier, L. P.
AU - Skorupski, Katherine A
AU - Burgess, K. E.
AU - Bergman, P. J.
AU - Carreras, J.
AU - Hahn, K.
AU - LeBlanc, A.
AU - Turek, M.
AU - Impellizeri, J.
AU - Fred, R.
AU - Wojcieszyn, J. W.
AU - Drobatz, K.
AU - Clifford, C. A.
PY - 2006/11
Y1 - 2006/11
N2 - Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA. Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA. Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples. Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and Sézary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83%. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46). Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.
AB - Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA. Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA. Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples. Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and Sézary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83%. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46). Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.
KW - Alkylator
KW - Chemotherapy
KW - Epitheliotropic lymphoma
KW - Mycosis fungoides
KW - Nitrosourea
KW - Skin
UR - http://www.scopus.com/inward/record.url?scp=33845693997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845693997&partnerID=8YFLogxK
U2 - 10.1892/0891-6640(2006)20[1389:ROCCEL]2.0.CO;2
DO - 10.1892/0891-6640(2006)20[1389:ROCCEL]2.0.CO;2
M3 - Article
C2 - 17186855
AN - SCOPUS:33845693997
VL - 20
SP - 1389
EP - 1397
JO - Journal of Veterinary Internal Medicine
JF - Journal of Veterinary Internal Medicine
SN - 0891-6640
IS - 6
ER -